Concert Pharmaceuticals, Inc. (CNCE)

NASDAQ: CNCE · IEX Real-Time Price · USD
4.45
-0.03 (-0.67%)
At close: Dec 9, 2022 4:00 PM
4.55
+0.10 (2.25%)
After-hours: Dec 9, 2022 5:31 PM EST
-0.67%
Market Cap 214.76M
Revenue (ttm) 42,000
Net Income (ttm) -126.81M
Shares Out 49.73M
EPS (ttm) -2.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 251,651
Open 4.44
Previous Close 4.48
Day's Range 4.41 - 4.62
52-Week Range 2.57 - 7.37
Beta 0.39
Analysts Buy
Price Target 17.75 (+298.9%)
Earnings Date Nov 7, 2022

About CNCE

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexin... [Read more]

Industry Biotechnology
IPO Date Feb 13, 2014
CEO Roger Tung
Employees 64
Stock Exchange NASDAQ
Ticker Symbol CNCE
Full Company Profile

Financial Performance

In 2021, CNCE's revenue was $32.58 million, an increase of 312.28% compared to the previous year's $7.90 million. Losses were -$80.05 million, 7.07% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CNCE stock is "Buy." The 12-month stock price forecast is 17.75, which is an increase of 298.88% from the latest price.

Price Target
$17.75
(298.88% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata ...

MELBOURNE, Australia--( BUSINESS WIRE )--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12th World Congress f...

2 weeks ago - Business Wire

Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates

Concert (CNCE) delivered earnings and revenue surprises of 1.69% and 97.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Brea...

MILAN--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Dr. Brett King, Yale University School of Medicine, presents CTP-543 THRIVE-AA1 Phase 3 data during the EADV Late Breaking News Session.

2 months ago - Business Wire

Recent Price Trend in Concert (CNCE) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Concert (CNCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Str...

3 months ago - Zacks Investment Research

Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #ConcertPharmaceuticals--Listen to Concert's on-demand webcast at the H.C. Wainwright Conference beginning at 7:00 am ET on September 12, 2022.

3 months ago - Business Wire

Wall Street Analysts Think Concert (CNCE) Could Surge 127%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 126.6% in Concert (CNCE). While the effectiveness of this highly sought-after metric is questionable, the positiv...

3 months ago - Zacks Investment Research

Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata...

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert's CTP-543 THRIVE-AA1 Phase 3 results will be presented as a late breaking oral presentation at EADV.

3 months ago - Business Wire

Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--BVF Partners and RA Capital have exercised their remaining tranche 1 warrants resulting in proceeds of $20.9 million to the Company.

3 months ago - Business Wire

Here's Why Concert Pharmaceuticals (CNCE) is a Great Momentum Stock to Buy

Does Concert Pharmaceuticals (CNCE) have what it takes to be a top stock pick for momentum investors? Let's find out.

3 months ago - Zacks Investment Research

What Makes Concert (CNCE) a Good Fit for "Trend Investing"

If you are looking for stocks that are well positioned to maintain their recent uptrend, Concert (CNCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Str...

4 months ago - Zacks Investment Research

Does Concert (CNCE) Have the Potential to Rally 158% as Wall Street Analysts Expect?

The mean of analysts' price targets for Concert (CNCE) points to a 158.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

4 months ago - Zacks Investment Research

Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Lags Revenue Estimates

Concert (CNCE) delivered earnings and revenue surprises of 34.44% and 93.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports second quarter 2022 financial results.

4 months ago - Business Wire

Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert announced positive topline results from its second Phase 3 clinical trial, THRIVE-AA2, evaluating CTP-543 in patients with alopecia a...

4 months ago - Business Wire

Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022.

4 months ago - Business Wire

Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences ...

6 months ago - Business Wire

Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of t...

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--CTP-543 Phase 2 results in alopecia areata published in JAAD.

6 months ago - Business Wire

Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common st...

6 months ago - Business Wire

Concert Pharmaceuticals Announces Pricing of Public Offering

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals announces pricing of public offering.

6 months ago - Business Wire

Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it intends to offer and sell 10,000,000 shares of its common stock in an underwritten registered publ...

6 months ago - Business Wire

Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert's THRIVE-AA1 Phase 3 study in alopecia areata meets primary endpoint for scalp hair regrowth and key secondary endpoints at both doses.

6 months ago - Business Wire

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ: CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent...

6 months ago - Benzinga